Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $20.88.
A number of equities analysts have issued reports on the company. StockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, October 21st. Finally, Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 18th.
View Our Latest Analysis on TEVA
In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. First Hawaiian Bank purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $723,000. CWA Asset Management Group LLC acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth $3,340,000. Central Pacific Bank Trust Division purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $935,000. GAMMA Investing LLC raised its stake in shares of Teva Pharmaceutical Industries by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 7,458 shares of the company's stock valued at $164,000 after acquiring an additional 2,297 shares in the last quarter. Finally, DGS Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after purchasing an additional 872 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.
Shares of Teva Pharmaceutical Industries stock opened at $20.97 on Monday. The firm has a 50-day simple moving average of $18.89 and a two-hundred day simple moving average of $18.05. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries has a fifty-two week low of $10.83 and a fifty-two week high of $22.80. The company has a market cap of $23.76 billion, a P/E ratio of -24.67, a price-to-earnings-growth ratio of 0.99 and a beta of 0.73.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.